2016 Fiscal Year Final Research Report
Color-coded intravital imaging demonstrates a transforming growth factor B antagonist selectively targets stromal cells in a human pancreatic-cancer orthotopic mouse model
Project/Area Number |
26830081
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor biology
|
Research Institution | Yokohama City University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Keywords | 膵癌 / 微小環境 / マウスモデル / 蛍光イメージング / SMAD4 / TGFーβ |
Outline of Final Research Achievements |
The present study describes the ability of color-coded intravital imaging to demonstrate the efficacy of a TGF-β inhibitor to target stroma in an orthotopic mouse model of pancreatic cancer. The PDOX, which has a high TGF-β expression level, was used in an orthotopic model in transgenic nude mice ubiquitously expressing red fluorescent protein (RFP). Fourteen mice were randomized into a control group (n = 7, vehicle, i.p., weekly, for 3 weeks) and a treated group (n = 7, SB431542 [TGF-β receptor type I inhibitor] 0.3 mg, i.p., weekly, for 3 weeks). Stromal cells expressing RFP were observed weekly for 3 weeks by real-time color-coded intravital imaging. The RFP fluorescence area from the stromal cells was significantly decreased in the TGF-β-inhibitor-treatment group compared to the control group. The present study demonstrated color-coded imaging in Fluorescent-PDOX mouse model can readily detect the selective anti-stromal-cell targeting of a TGF-β inhibitor.
|
Free Research Field |
消化器外科
|